Feng Bi

7.7k citations

141 papers · 4.4k indexed · 3 hit papers · h-index 33

Impact in

Cancer Research top 2%
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
Oncology top 2%
- Colorectal Cancer Treatments and Studies

Papers in ⓘ

Oncology 64
- Colorectal Cancer Treatments and Studies 30
- Cancer Treatment and Pharmacology 13
- Cancer Immunotherapy and Biomarkers 9
Pulmonary and Respiratory Medicine 55
- Gastric Cancer Management and Outcomes 26
- Lung Cancer Treatments and Mutations 12

Co-authors: Qiulin Tang (34 shared papers)Qiyong Gong (22 shared papers)Hongwei Xia (19 shared papers)Xiaoqi Huang (14 shared papers)Huanji Xu (13 shared papers)Su Lui (11 shared papers)Gongmin Zhu (3 shared papers)Lijiao Pei (2 shared papers)
Journals: Journal of Clinical Oncology (14 papers)Annals of Oncology (8 papers)Oncotarget (5 papers)Medical Oncology (4 papers)OncoTargets and Therapy (3 papers)
Partner nations: China United States South Korea

In The Last Decade

Feng Bi

134 papers receiving 4.4k citations

Hit Papers

align trajectories log scale

Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer 2021 · 265 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2021 Molecular Cancer
2021 Trends in Molecular Medicine
2015 The Lancet Oncology

Peers

Countries citing papers authored by Feng Bi

Since Specialization

Citations

This map shows the geographic impact of Feng Bi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Feng Bi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Feng Bi more than expected).

Fields of papers citing papers by Feng Bi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Feng Bi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Feng Bi. The network helps show where Feng Bi may publish in the future.

Co-authors

The 25 scholars most cited alongside Feng Bi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Feng Bi Line = papers co-authored together Feng Bi links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 141 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial The Lancet Oncology ·Jin Li, Shukui Qin, Rui‐Hua Xu, Thomas Yau, Brigette Ma, Hongming Pan, Jianming Xu, Yuxian Bai, Yihebali Chi, Liwei Wang, Kun‐Huei Yeh, Feng Bi, Ying Cheng, Anh T. Le, Jen-Kou Lin, Tianshu Liu, Dong Ma, Christian Kappeler, J. Kalmus, Tae Won Kim Hit paper breakdown →	2015	553
2	Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer Molecular Cancer ·Gongmin Zhu, Lijiao Pei, Hongwei Xia, Qiulin Tang, Feng Bi Hit paper breakdown →	2021	265
3	Ferroptosis in the tumor microenvironment: perspectives for immunotherapy Trends in Molecular Medicine ·Huanji Xu, Di Ye, Meiling Ren, Hongying Zhang, Feng Bi Hit paper breakdown →	2021	230
4	Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study Journal of Clinical Oncology ·Jianming Xu, Tae Won Kim, Lin Shen, Virote Sriuranpong, Hongming Pan, Rui‐Hua Xu, Weijian Guo, Sae‐Won Han, Tianshu Liu, Young Suk Park, Chunmei Shi, Yuxian Bai, Feng Bi, Joong Bae Ahn, Shukui Qin, Qi Li, Changping Wu, Dong Ma, Donghu Lin, Jin Li	2017	174
5	Identification and expansion of cancer stem cells in tumor tissues and peripheral blood derived from gastric adenocarcinoma patients Cell Research ·Tie Chen, Kun Yang, Jianhua Yu, Wentong Meng, Dandan Yuan, Feng Bi, Fang Liu, Jie Liu, Bing Dai, Xin‐Zu Chen, Fang Wang, Zeng Fan, Hong Xu, Jian‐Kun Hu, Xianming Mo	2011	147
6	miR‐137 targets Cdc42 expression, induces cell cycle G1 arrest and inhibits invasion in colorectal cancer cells International Journal of Cancer ·Ming Liu, Lang Nan, Meng Qiu, Feng Xu, Qiu Li, Qiulin Tang, Ji Chen, Xi Chen, Siyuan Zhang, Zhen Liu, Jitao Zhou, Yajie Zhu, Yu Deng, Yi Zheng, Feng Bi	2010	144
7	Early-Course Unmedicated Schizophrenia Patients Exhibit Elevated Prefrontal Connectivity Associated with Longitudinal Change Journal of Neuroscience ·Alan Anticevic, Xinyu Hu, Yuan Xiao, Junmei Hu, Fei Li, Feng Bi, Michael W. Cole, Aleksandar Savić, Genevieve Yang, Grega Repovš, John D. Murray, Xiao‐Jing Wang, Xiaoqi Huang, Su Lui, John H. Krystal, Qiyong Gong	2015	137
8	Disrupted Functional Brain Connectome in Patients with Posttraumatic Stress Disorder Radiology ·Du Lei, Kaiming Li, Lingjiang Li, Fuqin Chen, Xiaoqi Huang, Su Lui, Jing Li, Feng Bi, Qiyong Gong	2015	131
9	Two Patterns of White Matter Abnormalities in Medication-Naive Patients With First-Episode Schizophrenia Revealed by Diffusion Tensor Imaging and Cluster Analysis JAMA Psychiatry ·Huaiqiang Sun, Su Lui, Yao Li, Wei Deng, Yuan Xiao, Wenjing Zhang, Xiaoqi Huang, Junmei Hu, Feng Bi, Tao Li, John A. Sweeney, Qiyong Gong	2015	128
10	Disorganization of white matter architecture in major depressive disorder: a meta-analysis of diffusion tensor imaging with tract-based spatial statistics Scientific Reports ·Guangxiang Chen, Xinyu Hu, Lei Li, Xiaoqi Huang, Su Lui, Weihong Kuang, Hua Ai, Feng Bi, Zhongwei Gu, Qiyong Gong	2016	118
11	Brain grey matter volume alterations in late-life depression Journal of Psychiatry and Neuroscience ·Mingying Du, Jia Liu, Ziqi Chen, Xiaoqi Huang, Jing Li, Weihong Kuang, Yanchun Yang, Wei Zhang, Dong Zhou, Feng Bi, Keith M. Kendrick, Qiyong Gong	2014	114
12	miR-21 targets the tumor suppressor RhoB and regulates proliferation, invasion and apoptosis in colorectal cancer cells FEBS Letters ·Ming Liu, Qinlin Tang, Meng Qiu, Lang Nan, Mingxing Li, Yi Zheng, Feng Bi	2011	105
13	Altered Cortical Thickness Related to Clinical Severity But Not the Untreated Disease Duration in Schizophrenia Schizophrenia Bulletin ·Yi Xiao, Su Lui, Wei Deng, L. Yao, Wenjing Zhang, Shuhui Li, Mengjun Wu, Tianyu Xie, Yong He, Xiao‐Ying Huang, Jian Hu, Feng Bi, Tao Li, Qiyong Gong	2013	96
14	EGFR-PI3K-PDK1 pathway regulates YAP signaling in hepatocellular carcinoma: the mechanism and its implications in targeted therapy Cell Death and Disease ·Hongwei Xia, Xinyu Dai, Huangfei Yu, Sheng Zhou, Zhenhai Fan, Guoqing Wei, Qiulin Tang, Qiyong Gong, Feng Bi	2018	95
15	The lncRNA MALAT1 is a novel biomarker for gastric cancer metastasis Oncotarget ·Hongwei Xia, Qingjuan Chen, Ying Chen, Xiaojun Ge, Weibing Leng, Qiulin Tang, Ming Ren, Liang Chen, Dandan Yuan, Yucheng Zhang, Ming Liu, Qiyong Gong, Feng Bi	2016	93
16	Plasma miR-122 and miR-192 as potential novel biomarkers for the early detection of distant metastasis of gastric cancer Oncology Reports ·Qingjuan Chen, Xiaojun Ge, Yuchen Zhang, Hongwei Xia, Dandan Yuan, Qiulin Tang, Liang Chen, Xiaohui Pang, Weibing Leng, Feng Bi	2014	86
17	Functional MRI reveals different response inhibition between adults and children with ADHD. Neuropsychology ·Du Lei, Mingying Du, Min Wu, (unknown), Xiaoqi Huang, Xiaoxia Du, Feng Bi, Graham J. Kemp, Qiyong Gong	2015	78
18	Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma Cancer Science ·Dingwei Ye, Jiyan Liu, Aiping Zhou, Qing Zou, Hanzhong Li, Cheng Fu, Hailong Hu, Jian Huang, Shaoxing Zhu, Jie Jin, Lulin Ma, Jianming Guo, Jun Xiao, Se Hoon Park, Dahong Zhang, Xiusong Qiu, Yuanyuan Bao, Lilin Zhang, Wei Shen, Feng Bi	2020	75
19	Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial BMC Cancer ·Jifang Gong, Tianshu Liu, Qingxia Fan, Li Bai, Feng Bi, Shukui Qin, Jinwan Wang, Nong Xu, Ying Cheng, Yuxian Bai, Wei Liu, Liwei Wang, Lin Shen	2016	72
20	RhoA Regulates G1-S Progression of Gastric Cancer Cells by Modulation of Multiple INK4 Family Tumor Suppressors Molecular Cancer Research ·Siyuan Zhang, Qiulin Tang, Feng Xu, Yan Xue, Zipeng Zhen, Yu Deng, Ming Liu, Ji Chen, Surui Liu, Meng Qiu, Zhengyin Liao, Zhiping Li, Deyun Luo, Fang Shi, Yi Zheng, Feng Bi	2009	66

About Feng Bi

Feng Bi is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Hepatology and Cognitive Neuroscience, having authored 141 papers that have together received 4.4k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (30 papers), Gastric Cancer Management and Outcomes (26 papers), Cancer Treatment and Pharmacology (13 papers), Functional Brain Connectivity Studies (12 papers), Lung Cancer Treatments and Mutations (12 papers), Hepatocellular Carcinoma Treatment and Prognosis (10 papers), Cancer Immunotherapy and Biomarkers (9 papers) and MicroRNA in disease regulation (9 papers). The work is most often cited by research in Cancer Research (1.0k citations), Oncology (1.6k citations), Cognitive Neuroscience (823 citations), Hepatology (328 citations) and Pulmonary and Respiratory Medicine (996 citations). Feng Bi has collaborated with scholars based in China, United States and South Korea. Frequent co-authors include Qiulin Tang, Qiyong Gong, Hongwei Xia, Xiaoqi Huang, Huanji Xu, Su Lui, Gongmin Zhu, Lijiao Pei, Di Ye and Yuxian Bai. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Oncotarget, Medical Oncology and OncoTargets and Therapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact